摘要
目的探究慢性阻塞性肺疾病急性加重(AECOPD)合并高碳酸血症患者血清尿酸(SUA)、血肌酐(Scr)、β_(2)微球蛋白(β_(2)⁃MG)表达水平及临床意义。方法选择2021年2月至2022年6月间涡阳县人民医院接治的102例AECOPD合并高碳酸血症患者作为实验组研究对象,另选99名健康体检志愿者作为对照组,对比两组及不同疗效患者的血清SUA、Scr、β_(2)⁃MG水平,采用多元Logistic回归分析影响AECOPD合并高碳酸血症患者预后不良的危险因素。结果实验组患者治疗前血清SUA、Scr、β_(2)⁃MG水平明显高于对照组,差异有统计学意义(P<0.05);预后不良组治疗前血清SUA、Scr、β_(2)⁃MG水平均高于预后良好组,差异有统计学意义(P<0.05);采用多元Logistic回归分析可知,治疗前血清SUA、Scr、β_(2)⁃MG高水平是影响AECOPD合并高碳酸血症患者预后不良的危险因素(P<0.05)。结论治疗前血清SUA、SCr、β_(2)⁃MG高水平表达会影响AECOPD合并高碳酸血症患者的预后情况,应积极采取措施,预防不良事件的发生。
Objective To explore the expression levels and clinical significance of serum uric ac⁃id(SUA),serum creatinine(Scr)andβ_(2)⁃MG in patients with acute exacerbation of chronic obstructive pul⁃monary disease(AECOPD)combined with hypercapnia.Methods 102 patients with AECOPD combined with hypercapnia who were treated at Guoyang County People’s Hospital from February 2021 to June 2022 were selected as the experimental group,another 99 healthy volunteers were selected as the control group,the serum SUA,Scr,β_(2)⁃MG levels were compared between the two groups and patients with different curative ef⁃fects,and multiple logistic regression analysis was performed to analyze the risk factors for poor prognosis in patients with AECOPD complicated with hypercapnia.Results The serum levels of SUA,Scr andβ_(2)⁃MG in the experimental group were significantly higher than those in the control group before treatment,and the dif⁃ference was statistically significant(P<0.05).The serum SUA,Scr andβ_(2)⁃MG levels in the poor prognosis group were all higher before treatment than those in the good prognosis group,and the difference was statisti⁃cally significant(P<0.05).Multiple logistic regression analysis showed that high levels of serum SUA,Scr andβ_(2)⁃MG before treatment were risk factors for poor prognosis in patients with AECOPD complicated with hypercapnia(P<0.05).Conclusion The high level of serum SUA,SCr andβ_(2)⁃MG expression before treat⁃ment can affect the prognosis of AECOPD patients with hypercapnia,and measures should be taken to prevent the occurrence of adverse events.
作者
朱海波
苏永峰
蒋亚林
ZHU Haibo;SU Yongfeng;JIANG Yalin(Department of Respiratory and Critical Care Medicine,Guoyang People's Hospital,Bozhou,Anhui,China,233600;Department of Respiratory and Critical Care Medicine,Bozhou People's Hospital,Bozhou,Anhui,China,236804)
出处
《分子诊断与治疗杂志》
2023年第7期1195-1198,共4页
Journal of Molecular Diagnostics and Therapy
基金
安徽省重点研究与开发计划项目(202104j07020052)
亳州市重点研发计划(自筹经费)项目(bzzc2021019)。